市場調査レポート

糖化ヘモグロビン(HbA1c)検査市場

Glycated Haemoglobin (HbA1c) Testing Market

発行 ROOTS ANALYSIS 商品コード 310788
出版日 ページ情報 英文 159 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
糖化ヘモグロビン(HbA1c)検査市場 Glycated Haemoglobin (HbA1c) Testing Market
出版日: 2014年08月14日 ページ情報: 英文 159 Pages
概要

糖尿病は世界中で驚くべき割合で増加している慢性疾患です。現在糖尿病を患っている患者の数は3億8,200万人と推計され、この数は2035年までに5億9,200万人へ増加する見込みです。糖化ヘモグロビン(HbA1c)検査の導入はここ最近、徐々に増加しています。さらにラボ用分析装置もその既存位置を強める可能性があり、大きな成長はポイントオブケア(POC)装置によっても促進される見込みです。ラボ検査と比較して、即座の結果・正確性により、POC装置は家庭または診療所で用いることが可能です。加えて、生涯コストを考慮すると、POC検査はラボ検査より比較的安くなっています。特に新興市場における認識不足を克服する取り組みの拡大は、導入レベルをさらに押し上げると予測されています。

当レポートでは、世界の糖化ヘモグロビン(HbA1c)検査市場について調査し、市場概要、ポイントオブケア(POC)分析装置・ラボ分析装置市場の分析、地域別の市場規模・予測、SWOT分析および今後の見通しなどを提供しています。

第1章 序文

第2章 エグゼクティブサマリー

第3章 HbA1c検査:イントロダクション

  • 状況・背景
  • 糖尿病モニタリング
  • HbA1c検査
    • 検査の定義
    • 歴史的背景
    • 検査原理
    • HbA1c検査結果の説明
    • HbA1c検査の勧め
    • HbA1c検査のメリット
    • HbA1c検査の限界

第4章 市場概要

  • 本章の概要
  • HbA1c化学分析装置:メーカーの情勢
  • 競合分析:ポイントオブケアとラボ分析装置
  • その他の企業:コントロール、キット、試薬プロバイダー
  • HbA1c:機会規模のマッピング
  • 糖尿病とHbA1c:地域分析
    • BRIC諸国
    • 英国およびその他のEU5ヵ国
    • 米国

第5章 HbA1cポイントオブケア(POC)分析装置市場

  • イントロダクション
  • POC分析装置の製造検討事項
  • 分析装置の流通:企業数別
  • 分析装置の流通:サンプル数別
  • 分析装置の流通:分析時間別
  • 製品プロファイル:主な特徴
    • Afinion HbA1c 分析装置
    • DCAバンデージ分析装置
    • HemoCue 分析装置
    • A1c NOW+ 分析装置
    • in2it(II) 分析装置
  • POC市場の分析
    • カテゴリーI POC装置
    • カテゴリーII POC装置
  • 主要企業のプロファイル
    • ROHM
    • Alere
    • Trinity Biotech
    • Eurolyser
  • その他の企業
    • Chek Diagnostics
    • Radiometer
    • SD Biosensor
    • Ceragem Medisys

第6章 HbA1cラボ分析装置市場

  • 本章の概要
  • Siemens
    • 企業概要
    • 財務情報
    • 製品パイプライン
    • 生産施設
    • 将来の展望
  • Roche Laboratories
  • Abbott Laboratories
  • Bio-Rad Laboratories
  • ELITech Group
  • その他の企業

第7章 市場規模・予測

  • 本章の概要
  • 予測手法
  • HbA1c糖尿病検査市場:世界・地域別分析
  • HbA1c糖尿病検査市場:POC・ラボ用分析装置別の流通

第8章 SWOT分析

  • 本章の概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第9章 結論

  • HbA1c:大きなメリット
  • 主要な役割を果たす見込みのポイントオブケアデバイス
  • 新しいデリバリーモデルの登場
  • 診断企業の積極的な参加
  • 全体的な機会は大きい:「基本的シナリオ」において8.8%の成長を予測

第10章 付録1:表形式データ

第11章 付録2:企業リスト

図表

目次
Product Code: RA10020

Diabetes is a chronic disease growing at an alarming rate across the globe. Over 382 million people are estimated to be currently suffering from the disease; the number is likely to increase to 592 million by 2035.

With a very high prevalence, especially in some regions such as China and India, an increasing proportion of diabetic patients are likely to benefit from more efficient and accurate diagnostic tests in the future. Furthermore, an efficient measurement of the condition can help lower the rate of serious complications, such as heart attack and stroke. HbA1c, adapted for clinical testing to monitor diabetes in 1990s, is one such test; it can monitor and give average glucose results over the past 120 days. The test offers significant advantages over usual blood glucose monitoring assays; these include no prior fasting requirement, high sample stability, low day-to-day variation and limited impact from external physical factors such as stress.

The adoption of HbA1c tests has gradually risen in the recent past. While the laboratory analyzers are likely to strengthen their existing position, a significant growth will also be driven by Point of Care (POC) devices. POC devices bring a change in overall diabetes management and the lifestyle of the individual. Compared to laboratory tests, they can be used at home or physician's office with instantaneous results and accuracy. In addition, considering the lifetime costs, POC testing is comparatively cheaper than laboratory testing. Increased efforts to overcome lack of awareness, especially in emerging markets, are also expected to drive adoption levels further.

Synopsis

With a large number of devices already in market for HbA1c testing and more to come in the future years, HbA1c market is likely to shape up much better in the coming years. We have strong reasons to believe that the overall market outlook will stay positive in the mid-long term.

The "Glycated Haemoglobin (HbA1c) Testing Market, 2014-2024" report provides an exhaustive study of the growing market for HbA1c tests. Amongst other things, the report identifies HbA1c analyzers that are currently available for point of care and laboratory testing, and the high level trends which are likely to govern the evolution of this market in the US, EU5 and BRICS countries. The report also provides a competitive landscape wherein we have identified the most efficient POC devices in the market based on parameters such as user friendliness and other technical details.

One of the key objectives of this report is to understand the current and future state of the HbA1c diabetes monitoring market across various regions worldwide. This is done by analyzing the following:

  • Prevalence and growth of diabetes in different countries
  • Number of patients going for HbA1c tests
  • Frequency of HbA1c test per patient per year
  • Variable price points
  • Other technical details such as sample volume required, time taken for analysis, precision etc.

We have also provided a detailed view on the key drivers behind the growth of this market, likely challenges and upcoming threats under the SWOT framework. The base year for the report is 2014. The report provides mid -long term market forecasts for the period 2014 - 2024.

Example Highlights

  • 1.We identified 41 companies which are active in the HbA1c monitoring market. Amongst the 41 companies, nine manufacture both laboratory and POC analyzers. Except for the bigger companies which account for 41% of the overall industry, the nature of the market is quite fragmented.
  • 2.Currently, 108 HbA1c analyzers are commercially available. Of these, 71% are for laboratory use and the remaining 29% are for either home use or at physician's office.
  • 3.Specifically, for the POC testing, turbidimetry immunoassay and boronate affinity chromatography are the most commonly deployed principles (accounting for 50% and 35% of the POC devices respectively). The POC testing market has witnessed growing interest levels; acceptance is likely to rise further as a result of increased end-user convenience.
  • 4.For laboratory analyzers, Siemens, Beckman Coulter, Roche, Bio-Rad, Abbott, ELITech are some well-known players. The global distribution network of some of these players has positioned them to actively monetize this growing market.
  • 5.The overall market, in addition to an already well-established macro environment, will continue to benefit from continuous improvements in technology. In our base case, we expect the global HbA1c diabetes monitoring market to witness an annualized growth rate of 8.8%.

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on the current scenario of HbA1c testing market and the likely mid-long term evolution.

Chapter 3 provides a general introduction to the HbA1c testing for diabetes diagnosis and monitoring. We have discussed key concepts behind the test, principles involved, applications, test recommendations, advantages and limitations of the test.

Chapter 4 provides an overview of the competition in the HbA1c market. The chapter provides an extensive list of point of care and laboratory analyzers for HbA1c testing. It also discusses the evolution and adoption of HbA1c tests in the US, EU5 and BRICS countries.

Chapter 5 focuses on the point of care HbA1c analyzers. It covers the general considerations for POC devices, the market analysis for home and physician HbA1c analyzers, product profiles of specific devices and key company profiles.

Chapter 6 includes the company profiles of five key companies manufacturing laboratory analyzers for HbA1c monitoring. The profiles cover overview of the company, financial information, manufacturing facilities, recent partnerships and the future outlook of these companies.

Chapter 7 presents a scenario based approach to identify the future evolution of the industry. Given the uncertainty surrounding the adoption rates, we have done a multivariate sensitivity analysis to present different tracks of industry's evolution.

Chapter 8 provides our analysis of the strengths, weaknesses, opportunities and threats in the HbA1c diabetes monitoring market, capturing the key elements likely to influence future growth.

Chapter 9 summarizes the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapters 10 and 11 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.

Table of Contents

1. PREFACE

  • 1.1 Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. HbA1c TESTING: AN INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Diabetes Monitoring
  • 3.3. HbA1c Testing
    • 3.3.1. Test Definition
    • 3.3.2. Historical Background
    • 3.3.3. Test Principles
    • 3.3.4. HbA1c Test Results Interpretation
    • 3.3.5. HbA1c Test Recommendations
    • 3.3.6. Advantages of HbA1c Testing
    • 3.3.7. Limitations of HbA1c Testing

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. HbA1c Chemical Analyzers: Manufacturer's Landscape
  • 4.3. Competitive Analysis: Point of Care and Laboratory Analyzers
  • 4.4. Other Companies: Controls, Kits, Reagents Providers
  • 4.5. HbA1c: Mapping the Opportunity Size
  • 4.6. Diabetes and HbA1c: Regional Analysis
    • 4.6.1. BRICS Countries
    • 4.6.2. UK & Other EU5 Countries
    • 4.6.3. US

5. HbA1c POINT OF CARE ANALYZERS MARKET

  • 5.1. Introduction
  • 5.2. Manufacturing Considerations for POC Analyzers
  • 5.3. Distribution of Analyzers by Number of Companies
  • 5.4. Distribution of Analyzers by Sample Volume
  • 5.5. Distribution of Analyzers by Time Taken For Analysis
  • 5.6. Product Profiles: Key Characteristics
    • 5.6.1. Afinion HbA1c Analyzer
    • 5.6.2. DCA Vantage Analyzer
    • 5.6.3. HemoCue Analyzer
    • 5.6.4. A1c NOW+ Analyzer
    • 5.6.5. in2it(II) Analyzer
  • 5.7. POC Market Analysis
    • 5.7.1. Category I POC Devices
    • 5.7.2. Category 2 POC Devices
  • 5.8. Key Company Profiles
    • 5.8.1. ROHM
    • 5.8.2. Alere
    • 5.8.3. Trinity Biotech
    • 5.8.4. Eurolyser
  • 5.9. Other Companies
    • 5.9.1. Chek Diagnostics
    • 5.9.2. Radiometer
    • 5.9.3. SD Biosensor
    • 5.9.4. Ceragem Medisys

6. HbA1c LABORATORY ANALYZERS MARKET

  • 6.1. Chapter Overview
  • 6.2. Siemens
    • 6.2.1. Company Overview
    • 6.2.2. Financial Information
    • 6.2.3. Product Pipeline
    • 6.2.4. Manufacturing Facilities
    • 6.2.5. Future Outlook
  • 6.3. Roche Laboratories
    • 6.3.1. Company Overview
    • 6.3.2. Financial Performance
    • 6.3.3. Business Segments
    • 6.3.4. Product Portfolio
    • 6.3.5. Partnerships
    • 6.3.6. Manufacturing Facilities
    • 6.3.7. Future Outlook
  • 6.4. Abbott Laboratories
    • 6.4.1. Financial Performance
    • 6.4.2. Product Portfolio
    • 6.4.3. Partnerships
    • 6.4.4. Manufacturing Facilities
    • 6.4.5. Future Outlook
  • 6.5. Bio-Rad Laboratories
    • 6.5.1. Financial Performance
    • 6.5.2. Product Portfolio
    • 6.5.3. Partnerships
    • 6.5.4. Manufacturing Facilities
    • 6.5.5. Future Outlook
  • 6.6. ELITech Group
    • 6.6.1. Company Overview
    • 6.6.2. Product Portfolio
    • 6.6.3. Partnerships
    • 6.6.4. Future Outlook
  • 6.7. Other Companies
    • 6.7.1. Beckman Coulter
    • 6.7.2. Tosoh Bioscience
    • 6.7.3. Sebia
    • 6.7.4. Ortho Clinical Diagnostics

7. MARKET SIZE AND FORECAST

  • 7.1. Chapter Overview
  • 7.2. Forecast Methodology
  • 7.3. HbA1c Diabetes Testing Market: Global and Regional Analysis, 2014 - 2024
  • 7.4. HbA1c Diabetes Testing Market, 2014- 2024: Distribution by POC and Laboratory Analyzers

8. SWOT ANALYSIS

  • 8.1. Chapter Overview
  • 8.1. Strengths
  • 8.2. Weaknesses
  • 8.3. Opportunities
  • 8.4. Threats

9. CONCLUSION

  • 9.1. HbA1c: Significant Advantages
  • 9.2. Point of Care Devices Likely to Play a Key Role
  • 9.3. Emergence of New Delivery Models
  • 9.4. Active Participation of Diagnostics Companies
  • 9.4. Overall Opportunity is Big; We Project a 8.8% Growth in 'Base Scenario'

10. APPENDIX 1: TABULATED DATA

11. APPENDIX2: LIST OF COMPANIES

List of Figures

  • Figure 3.1 Diabetes Population: EU5, US, BRICS (Million)
  • Figure 3.2 Historic Timeline: Organizations Formed for Standardizing HbA1c Test Results
  • Figure 4.1 HbA1c Analyzers: Distribution by Number of Companies
  • Figure 4.2 HbA1c Analyzer Manufacturers: Distribution by Number of Analyzers
  • Figure 4.3 HbA1c Testing: Market Landscape
  • Figure 4.4 HbA1c Analyzers: Distribution by Place of Operation
  • Figure 4.5 Number of People Suffering From Diabetes in EU5, US, BRICS (Million)
  • Figure 4.6 Number of Deaths Due to Diabetes in EU5, US, BRICS, 2013 (Million)
  • Figure 4.7 Frequency of HbA1c Testing by Type of Insurance (Brazil)
  • Figure 4.8 Frequency of HbA1c Testing by Levels of HbA1c (Brazil)
  • Figure 4.9 HbA1c Values for Russians: By Age Group
  • Figure 4.10 The UK: HbA1c Adoption Trends, 2009-2012 (Diabetes Type 1)
  • Figure 4.11 The UK: HbA1c Adoption Trends, 2009-2012(Diabetes Type 2)
  • Figure 5.1 POC Analyzers: Distribution by Companies
  • Figure 5.2 POC Analyzers: Distribution by Place of Analysis
  • Figure 5.3 POC Analyzers: Distribution by Principle Used for Analysis
  • Figure 5.4 POC Analyzers: Distribution by Sample Volume Used for Analysis
  • Figure 5.5 POC Analyzers: Distribution by Time Taken for Analysis
  • Figure 5.6 POC Market Analysis: Category 1 Devices, Set 1
  • Figure 5.7 POC Market Analysis: Category 1 Devices, Set 2
  • Figure 5.8 POC Market Analysis: Category 2 Devices, Set 1
  • Figure 5.9 POC Market Analysis: Category 2 Devices, Set 2
  • Figure 5.10 ROHM Annual Sales, 2009-2014 (JPY Million)
  • Figure 5.11 ROHM Annual Sales: Distribution by Industrial Applications
  • Figure 5.12 Alere Annual Sales, 2009-2014 (USD Million)
  • Figure 5.13 Alere Annual Sales, 2012-2013: Distribution by Business Segment (USD Million)
  • Figure 5.14 Alere Annual Professional Diagnostic Sales, 2012-2013: Distribution by Industry (USD Million)
  • Figure 5.15 Alere Professional Diagnostic Sales, 2013: Distribution by Industry (USD Million, %)
  • Figure 5.16 Trinity Biotech Annual Sales, 2009-2013 (USD Million)
  • Figure 5.17 Trinity Biotech Annual Sales, 2012-2013: Distribution by Operating Segments (USD Million)
  • Figure 5.18 Trinity Biotech Clinical Laboratory Sales: Distribution by Operating Segments (USD Million)
  • Figure 5.19 Units of Premier Hb9210 Sold (2012-2013)
  • Figure 6.1 Siemens Annual Sales, 2009-2013 (EUR Million)
  • Figure 6.2 Siemens Annual Sales, 2012-2013: Distribution by Business Segment (EUR Million)
  • Figure 6.3 Siemens Annual Sales (2013): Distribution by Business Segment (EUR Million, %)
  • Figure 6.4 Siemens: Number of Analyzers byType of Diabetes Test
  • Figure 6.5 Siemens: Number of Manufacturing Sites
  • Figure 6.6 Roche Annual Sales, 2009-2013 (CHF Million)
  • Figure 6.7 Roche Annual Sales: Distribution by Business Segment (CHF Million, %)
  • Figure 6.8 Roche Diagnostics Annual Sales: Distribution by Segment
  • Figure 6.9 Professional Diagnostics Market: Distribution by Share of Major Pharma Industries
  • Figure 6.10 In-Vitro Diagnostics Market: Distribution by Share of Major Pharma Industries
  • Figure 6.11 Diabetes Market: Distribution by Share of Major Pharma Industries
  • Figure 6.12 Roche: Distribution by Number of Manufacturing Facilities
  • Figure 6.13 Abbott Laboratories Annual Sales, 2011-2013 (USD Million)
  • Figure 6.14 Abbott Laboratories Sales, 2013: Distribution by Business Segments (USD million, %)
  • Figure 6.15 Abbott Diagnostic Sales, 2013 (USD Million, %)
  • Figure 6.16 Bio-Rad Annual Sales, 2009-2013 (USD Million)
  • Figure 6.17 Bio-Rad Annual Sales: Distribution by Business Segment (USD Million)
  • Figure 6.18 Bio-Rad Annual Sales: Distribution by Business Segment (USD Million, %)
  • Figure 7.1 HbA1c Global Diabetes Monitoring Market Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Figure 7.2 HbA1c Regional Diabetes Monitoring Market Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Figure 7.3 HbA1c Global Laboratory Testing Market Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Figure 7.4 HbA1c Laboratory Testing Market Forecast, 2014 - 2024 (Distribution by Geography): Base Scenario USD Million)
  • Figure 7.5 HbA1c POC Testing Market Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Figure 7.6 HbA1c POC Testing Market Forecast, 2014 - 2024 (Distribution by Geography): Base Scenario (USD Million)
  • Figure 9.1 HbA1c Testing Market: Concluding Remarks
  • Figure 9.2 HbA1c Diabetes Monitoring Market, 2014, 2019, 2024 (USD Million)

List of Tables

  • Table 3.1 Characteristics of Type 1 and Type 2 Diabetes
  • Table 3.2 HbA1c Final Results: Influencing Factors
  • Table 3.3 Enzymatic Methods to Identify Hb Variants
  • Table 3.4 Different Principles to Measure Glycated Haemoglobin
  • Table 3.5 Conversion Values of HbA1c from One Unit to Another
  • Table 3.6 Interpretation of HbA1c Values
  • Table 4.1 POC HbA1c Analyzers: Test Details and Technical Parameters
  • Table 4.2 Laboratory Analyzers with HbA1c on Test Menu
  • Table 4.3 HbA1c Tests: Accessory Manufacturers
  • Table 4.4 Recommended Frequency of HbA1c Testing in EU5 Countries
  • Table 4.5 EU5: Proportion of People Getting Their HbA1c Tests Done Annually
  • Table 5.1 Afinion HbA1c Analyzer: Key Characteristics
  • Table 5.2 DCA Vantage Analyzer: Key Characteristics
  • Table 5.3 HemoCue: Key Characteristics
  • Table 5.4 A1c Now +: Key Characteristics
  • Table 5.5 in2it (II) HbA1c Analyzer: Key Characteristics
  • Table 5.6 POC Category 1Devices: Competitive Landscape
  • Table 5.7 POC Category 2 Devices: Competitive Landscape
  • Table 5.8 B-Analyst Measurement Chip Technical Details
  • Table 5.9 Technical Details of the B-Analyst Analyzer (Manufactured by Ushio Group)
  • Table 5.10 Approval of Afinion Technology for HbA1c Tests
  • Table 5.11 Afinion AS100 Chemical Analyzer: Technical Details
  • Table 5.12 Afinion AS100 Analyzer: HbA1c Test Details
  • Table 5.13 NycoCard: Technical Details
  • Table 5.14 NycoCard: Diabetes Test Parameters
  • Table 5.15 Trinity Biotech: Product Portfolio
  • Table 5.16 Trinity Biotech: Manufacturing Sites
  • Table 5.17 Eurolyser: Analyzers for HbA1c Monitoring
  • Table 6.1 Siemens: Diabetes Product Portfolio
  • Table 6.2 DCA Vantage: Tests Parameters
  • Table 6.3 Roche Diagnostics: Diabetes Product Portfolio
  • Table 6.4 Cobas b 101Analyzer: Test Parameters
  • Table 6.5 Abbott Molecular: Diabetes Product Portfolio
  • Table 6.6 Bio-Rad: HbA1c Product Portfolio
  • Table 6.7 ELITech Group: Analyzers for HbA1c Monitoring
  • Table 6.8 ELITech Group: Diabetes Product Portfolio
  • Table 6.9 Beckman Coulter: Analyzers for HbA1c Monitoring
  • Table 6.10 Tosoh Bioscience: Analyzers for HbA1c Monitoring
  • Table 6.11 Tosoh Bioscience: Marketed Systems by Geographies
  • Table 6.12 Ortho Clinical Diagnostics: Details of Analyzers
  • Table 8.1 HbA1c Testing: SWOT Analysis
  • Table 8.2 HbA1c Analyzers: Effect of Interference
  • Table 8.3 Blood Glucose Monitors
  • Table 10.1 Diabetes Population: EU5, US, BRICS (Million)
  • Table 10.2 Number of HbA1c Analyzers Manufactured by a Company
  • Table 10.3 HbA1c Market: Number of Analyzers by Companies
  • Table 10.4 Distribution of HbA1c Analyzers by Place of Operation
  • Table 10.5 Number of Deaths Due to Diabetes in EU5, US and BRICS (Million)
  • Table 10.6 Frequency of HbA1c Tests in Brazil
  • Table 10.7 HbA1c Values for Russians: By Age Group
  • Table 10.8 The UK HbA1c Adoption Rates, 2009-2012 (Diabetes Type 1)
  • Table 10.9 The UK HbA1c Adoption Rates, 2009-2012 (Diabetes Type 2)
  • Table 10.10 POC Analyzers: Distribution by Manufacturers
  • Table 10.11 POC Analyzers: Distribution by Place of Analysis
  • Table 10.12 POC Analyzers Distribution by Principle Used
  • Table 10.13 POC Analyzers: Distribution by Sample Volume Required
  • Table 10.14 POC Analyzers: Distribution by Time Taken for Analysis
  • Table 10.15 ROHM Annual Sales, 2009-2014 (JPY Million)
  • Table 10.16 Alere Annual Sales, 2009-2013(USD Million)
  • Table 10.17 Alere Annual Sales, 2012-2013: Distribution by Business Segment (USD Million)
  • Table 10.18 Alere Professional Diagnostic Sales, 2012-2013: Distribution by Industry (USD Million)
  • Table 10.19 Trinity Annual Sales, 2009-2013(USD Million)
  • Table 10.20 Trinity Annual Sales, 2012-2013: Distribution by Operating Segment (USD Million)
  • Table 10.21 Trinity Annual Sales, 2012-2013: Distribution by Clinical Laboratory Segment (USD Million)
  • Table 10.22 Units of Premier Hb9210 Analyzer Sold, 2012-2013
  • Table 10.23 Siemens Annual Sales, 2009-2013(EUR Million)
  • Table 10.24 Siemens Annual Sales, 2012-2013: Distribution by Business Segment (EUR Million)
  • Table 10.25 Siemens Healthcare: Number of Analyzers by Type of Diabetes Test
  • Table 10.26 Siemens: Number of Manufacturing Sites
  • Table 10.27 Roche Annual Sales, 2009-2013(CHF Million)
  • Table 10.28 Roche Annual Sales, 2013: Distribution by Business Segment (CHF Million)
  • Table 10.29 Roche: Number of Manufacturing Sites
  • Table 10.30 Abbott Laboratories Annual Sales, 2011-2013(USD Million)
  • Table 10.31 Bio-Rad Annual Sales, 2009-2013(USD Million)
  • Table 10.32 Bio-Rad Annual Sales, 2012-2013: Distribution by Business Segment (USD Million)
  • Table 10.33 HbA1c Global Diabetes Monitoring Market Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Table 10.34 HbA1c Regional Diabetes Monitoring Market Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Table 10.35 HbA1c Laboratory Testing Market Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Table 10.36 HbA1c Laboratory Testing Market Forecast, 2014 - 2024 (Distribution by Geography): Base Scenario (USD Million)
  • Table 10.37 HbA1c POC Testing Market Forecast, 2014 - 2024: Base Scenario (USD Million)
  • Table 10.38 HbA1c POC Testing Market Forecast, 2014 - 2024 (Distribution by Geography): Base Scenario (USD Million)
  • Table 10.39 HbA1c Global Diabetes Monitoring Market Forecast, 2014 - 2024: Conservative Scenario (USD Million)
  • Table 10.40 HbA1c Regional Diabetes Monitoring Market Forecast,2014 - 2024: Conservative Scenario (USD Million)
  • Table 10.41 HbA1c Laboratory Testing Market Forecast, 2014 - 2024: Conservative Scenario (USD Million)
  • Table 10.42 HbA1c Laboratory Testing Market Forecast, 2014 - 2024 (Distribution by Geography): Conservative Scenario (USD Million)
  • Table 10.43 HbA1c POC Testing Market Forecast, 2014 - 2024: Conservative Scenario (USD Million)
  • Table 10.44 HbA1c POC Testing Market Forecast, 2014 - 2024 (Distribution by Geography): Conservative Scenario (USD Million)
  • Table 10.45 HbA1c Global Diabetes Monitoring Market Forecast, 2014 - 2024: Optimistic Scenario (USD Million)
  • Table 10.46 HbA1c Regional Diabetes Monitoring Market Forecast, 2014 - 2024: Optimistic Scenario (USD Million)
  • Table 10.47 HbA1c Laboratory Testing Market Forecast, 2014 - 2024: Optimistic Scenario (USD Million)
  • Table 10.48 HbA1c Laboratory Testing Market Forecast, 2014 - 2024 (Distribution by Geography): Optimistic Scenario (USD Million)
  • Table 10.49 HbA1c POC Testing Market Forecast, 2014 - 2024: Optimistic Scenario (USD Million)
  • Table 10.50 HbA1c POC Testing Market Forecast, 2014 - 2024 (Distribution by Geography): Optimistic Scenario (USD Million)

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1. A Menarini
  • 2. Aalto Scientific
  • 3. Abbott
  • 4. AbD Serotec
  • 5. AC Immune SA
  • 6. Afinion
  • 7. Agappe
  • 8. Alere
  • 9. Alfa Wassermann
  • 10. Apex Bio
  • 11. ArkRay
  • 12. Ascletis
  • 13. AT&T
  • 14. Axis Shield
  • 15. Beckman Coulter
  • 16. Beijing Automotive Industry Holding
  • 17. Beijing Shining Sun
  • 18. Biohermes
  • 19. Bio-Rad
  • 20. Boditech
  • 21. Carolina Liquid
  • 22. Ceragem
  • 23. CFR Pharmaceuticals
  • 24. Chek Diagnostics
  • 25. Chiasma Inc.
  • 26. Ci-Co Healthcare
  • 27. Constitution Medical Inc.
  • 28. Convergent Technologies
  • 29. Diasys Diazyme
  • 30. Diazyme Laboratories
  • 31. Discuvia Ltd.
  • 32. Drew Scientific
  • 33. EKF Diagnostics
  • 34. ELITech
  • 35. Epocal
  • 36. Eurolyser
  • 37. FIOMI Diagnostics
  • 38. Freescale Semiconductors
  • 39. Hitachi
  • 40. Hitado
  • 41. Horiba Medical
  • 42. Human Diagnostics
  • 43. IDEV Technologies
  • 44. Immatics Biotechnologies
  • 45. Immco Diagnostics
  • 46. Inception Sciences Inc.
  • 47. Infopia
  • 48. Inovio
  • 49. Isis Pharma
  • 50. JANSSEN & Pharmacyclics
  • 51. Jeol
  • 52. KUKA
  • 53. Kyowa Medex
  • 54. LAB 21
  • 55. Mec Dynamics
  • 56. Merisant
  • 57. Mitsubishi
  • 58. Molecular Partners
  • 59. MorphoSys AG
  • 60. Myriad RBM, Inc.
  • 61. Nihon Kohden
  • 62. OptiMedica
  • 63. Ortho Clinical Diagnostics
  • 64. Oryzon Genomics
  • 65. Piramal Healthcare
  • 66. Pointe Scientific
  • 67. Polyphor Ltd.
  • 68. Prothena Corporation
  • 69. Quest Diagnostics
  • 70. Radiometer
  • 71. Randox laboratories
  • 72. Relay Technology Management
  • 73. Roche
  • 74. Rohm
  • 75. Sakae Corporation
  • 76. Samsung
  • 77. Sanwa Kagaku Kenkyusho Co. ltd
  • 78. SD Biosensor
  • 79. Sebia
  • 80. Sekisui Medical
  • 81. Shenzhen Lifotronic
  • 82. Siemens Healthcare
  • 83. Streck, Inc.
  • 84. Toshiba
  • 85. Tosoh Biosciences
  • 86. Trinity Biotech
  • 87. Tulip Reagents
  • 88. Valeant Pharmaceuticals
  • 89. Veropharm
  • 90. Versant Ventures
  • 91. Wako Pure Chemical industries
  • 92. Wiener laboratories
Back to Top